599 related articles for article (PubMed ID: 17241838)
1. Serum potassium monitoring for users of ethinyl estradiol/drospirenone taking medications predisposing to hyperkalemia: physician compliance and survey of knowledge and attitudes.
Mona Eng P; Seeger JD; Loughlin J; Oh K; Walker AM
Contraception; 2007 Feb; 75(2):101-7. PubMed ID: 17241838
[TBL] [Abstract][Full Text] [Related]
2. Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives.
Loughlin J; Seeger JD; Eng PM; Foegh M; Clifford CR; Cutone J; Walker AM
Contraception; 2008 Nov; 78(5):377-83. PubMed ID: 18929734
[TBL] [Abstract][Full Text] [Related]
3. The concomitant prescribing of ethinyl estradiol/drospirenone and potentially interacting drugs.
McAdams M; Staffa JA; Dal Pan GJ
Contraception; 2007 Oct; 76(4):278-81. PubMed ID: 17900437
[TBL] [Abstract][Full Text] [Related]
4. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R
J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629
[TBL] [Abstract][Full Text] [Related]
5. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives.
Seeger JD; Loughlin J; Eng PM; Clifford CR; Cutone J; Walker AM
Obstet Gynecol; 2007 Sep; 110(3):587-93. PubMed ID: 17766604
[TBL] [Abstract][Full Text] [Related]
6. Novel ethinyl estradiol-beta-cyclodextrin clathrate formulation does not influence the relative bioavailability of ethinyl estradiol or coadministered drospirenone.
Blode H; Schürmann R; Benda N
Contraception; 2008 Mar; 77(3):171-6. PubMed ID: 18279686
[TBL] [Abstract][Full Text] [Related]
7. A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol.
Kluft C; Endrikat J; Mulder SM; Gerlinger C; Heithecker R
Contraception; 2006 Apr; 73(4):336-43. PubMed ID: 16531162
[TBL] [Abstract][Full Text] [Related]
8. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
9. Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women.
Preston RA; White WB; Pitt B; Bakris G; Norris PM; Hanes V
Am J Hypertens; 2005 Jun; 18(6):797-804. PubMed ID: 15925739
[TBL] [Abstract][Full Text] [Related]
10. The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being.
Boschitsch E; Skarabis H; Wuttke W; Heithecker R
Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():34-40. PubMed ID: 11246600
[TBL] [Abstract][Full Text] [Related]
11. Use of drospirenone/ethinyl estradiol (DRSP/EE) among women with acne reduces acne treatment-related resources.
Joish VN; Boklage S; Lynen R; Schmidt A; Lin J
J Med Econ; 2011; 14(6):681-9. PubMed ID: 21892859
[TBL] [Abstract][Full Text] [Related]
12. Transfer of drospirenone to breast milk after a single oral administration of 3 mg drospirenone + 30 microg ethinylestradiol to healthy lactating women.
Blode H; Foidart JM; Heithecker R
Eur J Contracept Reprod Health Care; 2001 Sep; 6(3):167-71. PubMed ID: 11763981
[TBL] [Abstract][Full Text] [Related]
13. A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30 μg/drospirenone 3 mg administered in a 21/7 regimen versus ethinylestradiol 20 μg/drospirenone 3 mg administered in a 24/4 regimen.
Marr J; Gerlinger C; Kunz M
Eur J Obstet Gynecol Reprod Biol; 2012 May; 162(1):91-5. PubMed ID: 22391750
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial.
Koltun W; Lucky AW; Thiboutot D; Niknian M; Sampson-Landers C; Korner P; Marr J
Contraception; 2008 Apr; 77(4):249-56. PubMed ID: 18342647
[TBL] [Abstract][Full Text] [Related]
15. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea.
van Vloten WA; van Haselen CW; van Zuuren EJ; Gerlinger C; Heithecker R
Cutis; 2002 Apr; 69(4 Suppl):2-15. PubMed ID: 12096825
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone.
Ahrendt HJ; Nisand I; Bastianelli C; Gómez MA; Gemzell-Danielsson K; Urdl W; Karskov B; Oeyen L; Bitzer J; Page G; Milsom I
Contraception; 2006 Dec; 74(6):451-7. PubMed ID: 17157101
[TBL] [Abstract][Full Text] [Related]
17. Yasmin: the reason why.
Thorneycroft IH
Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():13-8; discussion 42-3. PubMed ID: 12659402
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing drospirenone.
Krunic A; Ciurea A; Scheman A
J Am Acad Dermatol; 2008 Jan; 58(1):60-2. PubMed ID: 17964689
[TBL] [Abstract][Full Text] [Related]
19. The association between drospirenone and hyperkalemia: a comparative-safety study.
Bird ST; Pepe SR; Etminan M; Liu X; Brophy JM; Delaney JA
BMC Clin Pharmacol; 2011 Dec; 11():23. PubMed ID: 22208934
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24/4-day regimen.
Hernádi L; Marr J; Trummer D; De Leo V; Petraglia F
Contraception; 2009 Jul; 80(1):18-24. PubMed ID: 19501211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
